SCAGLIOTTI, Giorgio Vittorio
SCAGLIOTTI, Giorgio Vittorio
ONCOLOGIA
141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
2016-01-01 Felip, E; Crinò, L; Kim, D-W; Spigel, D R; Nishio, M; Mok, T; Scagliotti, G; Cesic, D; Sutradhar, S; Shaw, A T
2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification
2022-01-01 Nicholson, Andrew G; Scagliotti, Giorgio; Tsao, Ming Sound; Yatabe, Yasushi; Travis, William D
[Evaluation of calcium metabolism and pituitary gonadotropin secretion during treatment with nifedipine]
1981-01-01 GOZZELINO G ;FUBINI A ;ISAIA GG ;SCAGLIOTTI G ;GAMNA G
[The electrocardiogram and arterial hypertension in primary hyperparathyroidism]
1979-01-01 Cottino, A; Marcolongo, M; Osella, D; Pascale, C; Scagliotti, G; Gamna, G; Molinatti, G M
[Ultrastructure of the pulmonary alveolus. Correlations with the endoalveolar tensioactive system]
1980-01-01 Pescetti, G; Gozzelino, F; Osella, D; Scagliotti, G
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
2011-01-01 Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP; on behalf of the EORTC Lung Cancer Group and the Italian Lung Cancer Project
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy
2016-01-01 Scagliotti, Giorgio; Nishio, Makoto; Satouchi, Miyako; Valmadre, Giuseppe; Niho, Seiji; Galetta, Domenico; Cortinovis, Diego; Benedetti, Fabio; Yoshihara, Eiji; Makris, Lukas; Inoue, Akira; Kubota, Kaoru
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
2014-01-01 Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
2005-01-01 Scagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid-Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG).
A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer
2013-01-01 J. Sandoval;J. Mendez-Gonzalez;E. Nadal;G. Chen;F. J. Carmona;S. Sayols;S. Moran;H. Heyn;M. Vizoso;A. Gomez;M. Sanchez-Cespedes;Y. Assenov;F. Muller;C. Bock;M. Taron;J. Mora;L. A. Muscarella;T. Liloglou;M. Davies;M. Pollan;M. J. Pajares;W. Torre;L. M. Montuenga;E. Brambilla;J. K. Field;L. Roz;M. Lo Iacono;G. V. Scagliotti;R. Rosell;D. G. Beer;M. Esteller
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
2020-01-01 Passiglia F.; Bironzo P.; Righi L.; Listi A.; Arizio F.; Novello S.; Volante M.; Scagliotti G.V.
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.
2011-01-01 Senan S; Cardenal F; Vansteenkiste J; Stigt J; Akyol F; De Neve W; Bakker J; Dupont JM; Scagliotti GV; Ricardi U; van Meerbeeck JP.
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
2009-01-01 Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J.
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
2006-01-01 CAPPUZZO F ;NOVELLO S ;DE MARINIS F ;SELVAGGI G ;SCAGLIOTTI GV ;BARBIERI F ;MAUR M ;PAPI M ;PASQUINI E ;BARTOLINI S ;MARINI L ;CRINÒ L
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
2020-01-01 Scagliotti G.; Moro-Sibilot D.; Kollmeier J.; Favaretto A.; Cho E.K.; Grosch H.; Kimmich M.; Girard N.; Tsai C.-M.; Hsia T.-C.; Brighenti M.; Schumann C.; Wang X.A.; Wijayawardana S.R.; Gruver A.M.; Wallin J.; Mansouri K.; Wacheck V.; Chang G.-C.
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma
2022-01-01 Tagliamento M.; Bironzo P.; Curcio H.; De Luca E.; Pignataro D.; Rapetti S.G.; Audisio M.; Bertaglia V.; Paratore C.; Bungaro M.; Olmetto E.; Artusio E.; Reale M.L.; Zichi C.; Capelletto E.; Carnio S.; Buffoni L.; Passiglia F.; Novello S.; Scagliotti G.V.; Di Maio M.
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients
2018-01-01 Baratelli, Chiara; Zichi, Clizia; Di Maio, Massimo*; Brizzi, Maria Pia; Sonetto, Cristina; Scagliotti, Giorgio Vittorio; Tampellini, Marco
A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomised trial.
2000-01-01 RINALDI M; CRINÒ L; SCAGLIOTTI GV; MOSCONI AM; DEMARINIS F; GRIDELLI C; SELVAGGI G; DELLA GIULIA M; DARWISH S; PORROZZI S; S. NOVELLO; CIPRI A; BARTOLUCCI R; CALANDRI C; TONATO M
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents
2019-01-01 Tucci M.; Roca E.; Ferrari L.; Pia A.; Dalla Volta A.; Bedussi F.; Buttigliero C.; Vittorio Scagliotti G.; Sigala S.; Berruti A.
Adapting clinical practice guidelines to a regional oncology network: the Piedmont experience
2007-01-01 GELORMINO E; PAGANO E; APPIANO S; CECCARELLI M; CIUFFREDA L; COMANDONE A; FARINA E; MERLETTI F; MUSSA A; PENNA A; PONTI A; RACITI I; SCAGLIOTTI GV; SEGNAN N; SENORE C; SISMONDI P; VINEIS P; BERTETTO O; CICCONE G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials | 2016 | Felip, E; Crinò, L; Kim, D-W; Spigel, D R; Nishio, M; Mok, T; Scagliotti, G; Cesic, D; Sutradhar, S; Shaw, A T | |
| 2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification | 2022 | Nicholson, Andrew G; Scagliotti, Giorgio; Tsao, Ming Sound; Yatabe, Yasushi; Travis, William D | |
| [Evaluation of calcium metabolism and pituitary gonadotropin secretion during treatment with nifedipine] | 1981 | GOZZELINO G ;FUBINI A ;ISAIA GG ;SCAGLIOTTI G ;GAMNA G | |
| [The electrocardiogram and arterial hypertension in primary hyperparathyroidism] | 1979 | Cottino, A; Marcolongo, M; Osella, D; Pascale, C; Scagliotti, G; Gamna, G; Molinatti, G M | |
| [Ultrastructure of the pulmonary alveolus. Correlations with the endoalveolar tensioactive system] | 1980 | Pescetti, G; Gozzelino, F; Osella, D; Scagliotti, G | |
| A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) | 2011 | Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP; on behalf of the EORTC Lung Cancer Group and the Italian Lung Cancer Project | |
| A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy | 2016 | Scagliotti, Giorgio; Nishio, Makoto; Satouchi, Miyako; Valmadre, Giuseppe; Niho, Seiji; Galetta, Domenico; Cortinovis, Diego; Benedetti, Fabio; Yoshihara, Eiji; Makris, Lukas; Inoue, Akira; Kubota, Kaoru | |
| A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. | 2014 | Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC | |
| A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) | 2005 | Scagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid-Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG). | |
| A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer | 2013 | J. Sandoval;J. Mendez-Gonzalez;E. Nadal;G. Chen;F. J. Carmona;S. Sayols;S. Moran;H. Heyn;M. Vizoso;A. Gomez;M. Sanchez-Cespedes;Y. Assenov;F. Muller;C. Bock;M. Taron;J. Mora;L. A. Muscarella;T. Liloglou;M. Davies;M. Pollan;M. J. Pajares;W. Torre;L. M. Montuenga;E. Brambilla;J. K. Field;L. Roz;M. Lo Iacono;G. V. Scagliotti;R. Rosell;D. G. Beer;M. Esteller | |
| A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design | 2020 | Passiglia F.; Bironzo P.; Righi L.; Listi A.; Arizio F.; Novello S.; Volante M.; Scagliotti G.V. | |
| A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. | 2011 | Senan S; Cardenal F; Vansteenkiste J; Stigt J; Akyol F; De Neve W; Bakker J; Dupont JM; Scagliotti GV; Ricardi U; van Meerbeeck JP. | |
| A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer | 2009 | Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J. | |
| A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. | 2006 | CAPPUZZO F ;NOVELLO S ;DE MARINIS F ;SELVAGGI G ;SCAGLIOTTI GV ;BARBIERI F ;MAUR M ;PAPI M ;PASQUINI E ;BARTOLINI S ;MARINI L ;CRINÒ L | |
| A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients | 2020 | Scagliotti G.; Moro-Sibilot D.; Kollmeier J.; Favaretto A.; Cho E.K.; Grosch H.; Kimmich M.; Girard N.; Tsai C.-M.; Hsia T.-C.; Brighenti M.; Schumann C.; Wang X.A.; Wijayawardana S.R.; Gruver A.M.; Wallin J.; Mansouri K.; Wacheck V.; Chang G.-C. | |
| A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma | 2022 | Tagliamento M.; Bironzo P.; Curcio H.; De Luca E.; Pignataro D.; Rapetti S.G.; Audisio M.; Bertaglia V.; Paratore C.; Bungaro M.; Olmetto E.; Artusio E.; Reale M.L.; Zichi C.; Capelletto E.; Carnio S.; Buffoni L.; Passiglia F.; Novello S.; Scagliotti G.V.; Di Maio M. | |
| A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients | 2018 | Baratelli, Chiara; Zichi, Clizia; Di Maio, Massimo*; Brizzi, Maria Pia; Sonetto, Cristina; Scagliotti, Giorgio Vittorio; Tampellini, Marco | |
| A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomised trial. | 2000 | RINALDI M; CRINÒ L; SCAGLIOTTI GV; MOSCONI AM; DEMARINIS F; GRIDELLI C; SELVAGGI G; DELLA GIULIA M; DARWISH S; PORROZZI S; S. NOVELLO; CIPRI A; BARTOLUCCI R; CALANDRI C; TONATO M | |
| Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents | 2019 | Tucci M.; Roca E.; Ferrari L.; Pia A.; Dalla Volta A.; Bedussi F.; Buttigliero C.; Vittorio Scagliotti G.; Sigala S.; Berruti A. | |
| Adapting clinical practice guidelines to a regional oncology network: the Piedmont experience | 2007 | GELORMINO E; PAGANO E; APPIANO S; CECCARELLI M; CIUFFREDA L; COMANDONE A; FARINA E; MERLETTI F; MUSSA A; PENNA A; PONTI A; RACITI I; SCAGLIOTTI GV; SEGNAN N; SENORE C; SISMONDI P; VINEIS P; BERTETTO O; CICCONE G |